CPX-351治疗高危AML患者的长期真实世界证据显示高阴性MRD率与延长OS
该回顾性研究纳入法国和意大利36个中心的168例新诊断、未经治疗的t-AML或MRC-AML患者,接受1或2个周期CPX-351诱导。中位随访3年,中位OS为13.3个月;MRD低于10^-3者中位OS为20.4个月,高于10^-3者为12.9个月(P=.006)。多因素分析中仅MRD>10^-3与更差OS相关(HR 2.6,95%CI 1.2-5.5,P=.013)。
要点
- CPX-351治疗t-AML或MRC-AML患者中位OS为13.3个月,中位随访3年。
- MRD低于10^-3者中位OS为20.4个月,高于10^-3者为12.9个月(P=.006)。
- 多因素分析中仅MRD>10^-3与更差OS相关(HR 2.6,95%CI 1.2-5.5,P=.013)。
核心结论
- 达到MRD阴性有助于改善总体人群的OS,可能也有助于接受移植患者的OS。
- 这些数据为两项正在进行的、以MRD为主要终点的研究提供了依据。
研究设计与样本
- 回顾性收集法国和意大利36个中心168例患者的数据。
- 患者均年龄>18岁,为新诊断、未经治疗的t-AML或MRC-AML,接受1或2个周期CPX-351诱导。
主要发现
- 中位随访3年,中位OS为13.3个月。
- MRD低于10^-3者中位OS为20.4个月,MRD高于10^-3者为12.9个月(P=.006)。
- 多因素分析中仅MRD>10^-3与更差OS相关(HR 2.6,95%CI 1.2-5.5,P=.013)。
- 接受造血干细胞移植且MRD<10^-3者中位OS未达到,MRD≥10^-3者为26.0个月(P=.06)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on measurable residual disease (MRD) and long-term clinical outcome using CPX-351 in AML in real life. We retrospectively collected data from 168 patients in 36 centers in France and Italy who had received 1 or 2 cycles of induction with CPX-351. All patients were aged >18 years and had newly diagnosed, untreated t-AML or MRC-AML. With a median follow-up of 3 years, the median overall survival (OS) was 13.3 months. The median OS was 20.4 months vs 12.9 months for patients with MRD below or above 10-3, respectively (P = .006). In a multivariate analysis, only MRD >10-3 was associated with a poorer OS (hazard ratio, 2.6; 95% confidence interval, 1.2-5.5; P = .013). We also observed a trend toward a better median OS in patients who underwent hematopoietic stem cell transplantation with MRD <10-3 (not reached vs 26.0 months; P = .06). Achievement of MRD negativity contributed to the improvement of OS in the overall population and, maybe, in patients receiving transplant. These data provide the rationale for the 2 ongoing studies evaluating CPX-351 vs 7+3 in non-MRC-AML and non-t-AML using MRD as the primary end point for ALFA-2101 phase 2 clinical trial and event-free survival for AMLSG 30-18 phase 3 clinical trial.
引用
- Cluzeau T, Guolo F, Chiche E, et al. Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS. Blood Adv. 2025. PMID: 39454204. doi:10.1182/bloodadvances.2024014279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。